Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | GCGR | P47871 | 11/20 | 0.46 |
| ▸ | GLP1R | P43220 | 1/20 | 0.46 |
| ▸ | GIPR | P48546 | 1/20 | 0.46 |
| ▸ | GCG | P01275 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2662296 | 0.91 | EPHX2 (0.55) | EPHX2GCGRGLP1RGIPRGCG | |
| SCHEMBL6186578 | 0.83 | EPHX1 (0.46) | EPHX2GCGRGCGSMN1; SMN2 | |
| SCHEMBL4080823 | 0.83 | GCGR (0.45) | EPHX2GCGRGCG | |
| SCHEMBL4081999 | 0.83 | GCGR (0.62) | EPHX2GCGRGLP1RGIPR | |
| SCHEMBL4092724 | 0.82 | GCGR (0.51) | EPHX2GCGR | |
| SCHEMBL4096552 | 0.81 | GCGR (0.53) | GCGRGCG | |
| SCHEMBL4087807 | 0.81 | GCGR (0.43) | EPHX2GCGRGCG | |
| SCHEMBL4087617 | 0.80 | GCGR (0.47) | GCGRGCG | |
| SCHEMBL2663082 | 0.79 | GCGR (0.52) | HDAC8EPHX2GCGRGIPRSMN1; SMN2 | |
| SCHEMBL4085143 | 0.74 | EPHX2 (0.55) | EPHX2GCGRGLP1RGIPRGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | HDAC8 2820/4885EPHX2 3463/4885GCGR 3/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | HDAC8 2820/4885EPHX2 3463/4885GCGR 3/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | HDAC8 2820/4885EPHX2 3463/4885GCGR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.